Prognostic value of minimal residual disease in relapsed childhood acute lymphoblastic leukaemia

Lancet

Volumn 358, Issue 9289, 2001, Pages 1239-1241

  Eckert, Cornelia ^a,c   Biondi, Andrea ^b   Seeger, Karlheinz ^a   Cazzaniga, Giovanni ^b   Hartmann, Reinhard ^a   Beyermann, Birgit ^a   Pogodda, Michael ^a   Proba, Jutta ^a   Henze, Günter ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

^b UNIVERSITY OF MILANO BICOCCA   (Italy)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CANCER SURVIVAL; CANCER THERAPY; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; LONG TERM CARE; MINIMAL RESIDUAL DISEASE; MULTIPLE ORGAN FAILURE; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROGNOSIS; SEPSIS; SEPTICEMIA;

EID: 0035856232     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(01)06355-3     Document Type: Article

References (5)

1. Six-year experience with a comprehensive approach to the treatment of recurrent childhood acute lymphoblastic leukemia (ALL-REZ BFM 85). A relapse study of the BFM Group
2. Relapsed lymphoblastic leukaemia in children: A continuing challenge
3. Chemotherapy for relapsed childhood acute lymphoblastic leukemia
4. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia
5. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood